Loading clinical trials...
Loading clinical trials...
A Pilot Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Treatment of Relapsed or Refractory Solid Tumors
Conditions
Interventions
Magnetic Resonance-Guided High Intensity Focused Ultrasound
Lyso-thermosensitive Liposomal Doxorubicin
Locations
1
United States
Children's National Hospital
Washington D.C., District of Columbia, United States
Start Date
November 10, 2022
Primary Completion Date
December 23, 2024
Completion Date
December 23, 2024
Last Updated
January 1, 2025
NCT04570423
NCT07177937
NCT07489378
NCT06926283
NCT07181681
NCT07387068
Lead Sponsor
Children's National Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions